BRAF and colorectal cancer: The overwhelming majority of mutation of BRAF was conducive to gain-of-function and plays a role of oncogene, with high frequency of V600 E variant, which had been uncovered as a treatment target in papillary thyroid cancer, lung cancer, and colorectal cancer [31–33].